The validity of progression-free survival 2 as a surrogate trial end point for overall survival.
Rachel G WoodfordDeborah Di-Xin ZhouPeey Sei KokSarah Sally J LordMichael L FriedlanderIan C MarschnerR John SimesChee Khoon LeePublished in: Cancer (2022)
Across diverse tumors and therapies, the treatment effect on PFS-2 correlated moderately with the treatment effect on OS. PFS-2 performed consistently better than PFS-1 and ORR, regardless of postprogression treatment and postprogression survival. PFS-2 should be included as a key trial end point in future randomized trials of solid tumors.